Advertisement

EpiPen CEO To Testify About Price Hikes03:42
Download

Play
Timothy Lunceford Stevens, who suffers from autoimmune diseases and allergies, holds an EpiPen during a protest against its price hikes on Aug. 30, 2016 in New York City.  (Drew Angerer/Getty Images)
Timothy Lunceford Stevens, who suffers from autoimmune diseases and allergies, holds an EpiPen during a protest against its price hikes on Aug. 30, 2016 in New York City. (Drew Angerer/Getty Images)
This article is more than 4 years old.

The CEO of Mylan, the company that recently dramatically raised the price of its EpiPen allergy treatment, is expected to tell the House Oversight Committee this afternoon that the company does not make huge profits off of the lifesaving devices and has no plans to lower the price.

USA Today reporter Jayne O'Donnell joins Here & Now's Jeremy Hobson to discuss her recent reporting. She discovered that the CEO's mother, as head of the National Association of State Boards of Education, was behind a push requiring schools to purchase EpiPens.

The National Association of State Boards of Education has issued a statement in response to O'Donnell’s story.

Correction: In this segment, USA Today reporter Jayne O’Donnell incorrectly identified Gayle Manchin as being affiliated with the National School Boards Association (NSBA). She is the former head of the Association of State Boards of Education (NASBE), a different group.

Guest

Jayne O'Donnell, healthcare policy reporter for USA Today. She tweets @JayneODonnell.

This article was originally published on September 21, 2016.

This segment aired on September 21, 2016.

Related:

Advertisement

Advertisement